Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) EBIT (2016 - 2025)

Historic EBIT for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $20075.0.

  • Immucell's EBIT rose 10349.19% to $20075.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 20296.71%. This contributed to the annual value of -$1.6 million for FY2024, which is 7146.6% up from last year.
  • Per Immucell's latest filing, its EBIT stood at $20075.0 for Q3 2025, which was up 10349.19% from $569562.0 recorded in Q2 2025.
  • Over the past 5 years, Immucell's EBIT peaked at $1.1 million during Q1 2025, and registered a low of -$2.3 million during Q1 2023.
  • For the 5-year period, Immucell's EBIT averaged around -$373279.7, with its median value being -$337338.5 (2021).
  • As far as peak fluctuations go, Immucell's EBIT crashed by 122353.45% in 2022, and later surged by 47247.68% in 2025.
  • Quarter analysis of 5 years shows Immucell's EBIT stood at $145412.0 in 2021, then plummeted by 1223.53% to -$1.6 million in 2022, then increased by 27.53% to -$1.2 million in 2023, then soared by 152.48% to $621395.0 in 2024, then crashed by 96.77% to $20075.0 in 2025.
  • Its last three reported values are $20075.0 in Q3 2025, $569562.0 for Q2 2025, and $1.1 million during Q1 2025.